Arcus Biosciences, Inc. RCUS

HAYWARD, Calif., September 22, 2026--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and inflammatory diseases, announced today that it will host an in-person investor event with a live webcast on Tuesday, October 20, 2026, beginning at 8:30 AM ET, in New York City.

HAYWARD, Calif., September 09, 2026--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted one new employee options to purchase a total of 26,350 shares of the Company’s common stock at an exercise price per share of $29.06, which was t

HAYWARD, Calif., August 26, 2026--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, announced that its management team will participate in the following upcoming investor conferences in September:

On July 22, Arcus Biosciences, Inc. (NYSE:RCUS) and Summit Therapeutics Inc. (NASDAQ:SMMT) announced a major clinical trial collaboration to combine Arcus’s casdatifan (an investigational HIF-2α inhibitor) with Summit’s ivonescimab (an investigational PD-1/VEGF bispecific antibody). The study aims to evaluate the safety and efficacy of this combination in clear cell renal cell carcinoma (ccRCC), including first-line […]

Arcus Biosciences (RCUS) Casdatifan therapy for renal cell carcinoma could be launched in 2028 and p

The fair value estimate for Arcus Biosciences has shifted from US$35.75 to US$38.00, signaling a modest reset in where analysts think the stock could reasonably trade. That move tracks with recent updates that balance enthusiasm around the kidney cancer franchise, especially casdatifan, against questions about how quickly those programs can translate into durable commercial performance. As you read on, you will see how this evolving narrative might shape your view of Arcus Biosciences over...

Moby summary of Arcus Biosciences, Inc.'s Q2 2026 earnings call

Arcus Biosciences (RCUS) delivered earnings and revenue surprises of +26.53% and +186.21%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

HAYWARD, Calif., August 05, 2026--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today reported financial results for the second quarter ended June 30, 2026, and provided a pipeline update on its clinical-stage investigational molecules and discovery programs.

Summit Therapeutics Inc (SMMT) reports robust financial health and significant progress in clinical trials, despite facing competitive and regulatory challenges.